Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

[1]  L. Sequist,et al.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management , 2022, Nature Reviews Clinical Oncology.

[2]  S. Pignata,et al.  Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients , 2022, Cancers.

[3]  D. Lambrechts,et al.  c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial , 2022, BMC Medicine.

[4]  I. Ray-Coquard,et al.  Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy , 2021, Current Oncology Reports.

[5]  S. Maurya,et al.  The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers. , 2021, Epigenomics.

[6]  S. A. K. Rasheed,et al.  The emerging roles of Gα12/13 proteins on the hallmarks of cancer in solid tumors , 2021, Oncogene.

[7]  S. Pignata,et al.  Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study , 2021, Cancers.

[8]  Jia Kang,et al.  A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy , 2021, Journal of drug targeting.

[9]  Y. Yarden,et al.  EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance , 2021, Cancers.

[10]  D. Katsaros,et al.  Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study , 2021, International Journal of Gynecological Cancer.

[11]  G. Mills,et al.  Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling , 2020, Cancer Research.

[12]  S. Pignata,et al.  Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience , 2020, Cells.

[13]  D. Mukherji,et al.  Resistance Mechanisms to Anti-angiogenic Therapies in Cancer , 2020, Frontiers in Oncology.

[14]  G. Pagès,et al.  The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor , 2020, Theranostics.

[15]  M. Joghataei,et al.  The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme. , 2019, Cancer biotherapy & radiopharmaceuticals.

[16]  Danielle M. Enserro,et al.  Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Wong,et al.  Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress , 2019, Journal of Experimental & Clinical Cancer Research.

[18]  T. Seidal,et al.  Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II. , 2018, International journal of oncology.

[19]  A. Tomassetti,et al.  Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth , 2018, Journal of Experimental & Clinical Cancer Research.

[20]  F. Takahashi‐Yanaga,et al.  The role of angiotensin II in cancer metastasis: Potential of renin-angiotensin system blockade as a treatment for cancer metastasis. , 2018, Biochemical pharmacology.

[21]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[22]  E. Kohn,et al.  The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Jain,et al.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy , 2017, Science Translational Medicine.

[24]  D. Radisky,et al.  EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review , 2017, Genes & cancer.

[25]  Jian-Bing Fan,et al.  Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes , 2017, Clinical Cancer Research.

[26]  T. Köhler,et al.  Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? , 2016, Molecular Cancer.

[27]  A. Tomassetti,et al.  Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome , 2015, Oncotarget.

[28]  Jacobus Pfisterer,et al.  Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.

[29]  E. Berns,et al.  Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy , 2015, Targeted Oncology.

[30]  E. Goode,et al.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. , 2014, Journal of the National Cancer Institute.

[31]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[32]  A. Tomassetti,et al.  An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response , 2013, BMC Genomics.

[33]  T. Tokuyasu,et al.  Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance , 2013, Clinical Cancer Research.

[34]  A. Tomassetti,et al.  Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer , 2012, Oncogene.

[35]  D. Cheresh,et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.

[36]  Benjamin Haibe-Kains,et al.  Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer , 2012, PloS one.

[37]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[38]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[39]  Q. Sheng,et al.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer , 2011, British Journal of Cancer.

[40]  Helen X. Chen,et al.  Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.

[41]  A. Oza,et al.  A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). , 2010, Gynecologic oncology.

[42]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[43]  A. Maity,et al.  EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. , 2006, Cancer research.

[44]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[45]  J. Sulkes,et al.  Ovarian angiotensin-converting enzyme activity in humans: relationship to estradiol, age, and uterine pathology. , 1996, The Journal of clinical endocrinology and metabolism.

[46]  S. Canevari,et al.  Anti‐tumor efficacy of an anti‐epidermal‐growth‐factor‐ receptor monoclonal antibody and its F(ab′)2 fragment against high‐ and low‐egfr‐expressing carcinomas in nude mice , 1995, International journal of cancer.

[47]  M. Stack,et al.  Activated epidermal growth factor receptor in ovarian cancer. , 2009, Cancer treatment and research.

[48]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..